News | November 06, 2024
Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Subscribe To Our Newsletter & Stay Updated
